Contrive Datum Insights has published "Medicine Filling And Manufacturing Equipment Market Size, Share & Industry Analysis, By Type (Tableting Machine, Mixed Granulation Equipment, Centrifugal Drying Equipment, Filling and Sealing Equipment, Others), Application (Injection Medicine, Vaccine, Oral Solution, Other), End user (Pharmaceutical Manufacturers, Contract Manufacturing Organizations, Biotechnology Companies), Technology (Automatic, Semi-Automatic, Manual), Production capacity (Medium-Capacity Systems, High-Capacity Systems, Low-Capacity Systems), and Regional Forecast, 2026-2034". The study sizes the global medicine filling and manufacturing equipment market at USD 15.8 billion in 2025 and projects growth from USD 16.88 billion in 2026 to USD 28.58 billion by 2034, a compound annual growth rate of 6.8% across the forecast period.
Medicine filling and manufacturing equipment covers the machinery used to convert bulk pharmaceutical formulations into finished dosage forms, including granulators and dryers that prepare and condition powders for tableting, tablet presses that compress the finished solid dose, and filling and sealing lines that dose liquids, suspensions and injectable products into vials, ampoules, syringes or blister packs under controlled or aseptic conditions. Buyers are pharmaceutical manufacturers building or expanding production lines, contract manufacturing organizations serving multiple drug sponsors, and biotechnology companies scaling clinical or commercial output, each selecting equipment based on the dosage form, batch size and containment level their specific product line requires.
Expansion of injectable and biologic manufacturing capacity
Expansion of injectable and biologic manufacturing capacity is the largest single contributor to the market's growth over the forecast period, and the study rates its impact high. Against a market growing at 6.8% a year, the type lines exposed to it move fastest: Others compounds at 10.81%, taking its share of revenue from 10% to 14% and its value from USD 1.58 billion to USD 4 billion.
The study also runs a bull case: faster biologic and vaccine capacity buildout and quicker replacement of manual lines with automated systems lift equipment purchases across all regions. That path ends 2034 at USD 32.01 billion, above the USD 28.58 billion base case.
Against that, slower capital spending on new manufacturing capacity and longer equipment replacement cycles, particularly among smaller contract manufacturers, hold purchases below the base case. On that reading 2034 revenue stops at USD 25.72 billion. The weight of the problem sits in Tableting Machine: 28% of 2025 revenue growing at 4.98%, well under the market's 6.8%.
Key Players Compete on Tableting Machine Volume and Others Growth
The type axis, not the regional one, is what divides the field. Tableting Machine is the volume position, 28% of 2025 revenue at USD 4.42 billion, holding 24% through 2034, and it is defended by scale. Others is the growth position at 10.81%, and it is open. Strength in one does not carry into the other.
Other Findings in the Study
| Segment | Led 2025 by | Share & value | Fastest-growing |
|---|---|---|---|
| Application | Injection Medicine | 34% · USD 5.37 billion | Vaccine 8.22% |
| End user | Pharmaceutical Manufacturers | 52% · USD 8.22 billion | Contract Manufacturing Organizations 8.31% |
| Technology | Automatic | 48% · USD 7.58 billion | — |
| Production capacity | Medium-Capacity Systems | 42% · USD 6.64 billion | High-Capacity Systems 8.76% |
- Regionally, the lead sits with Asia Pacific: 38% of 2025 global revenue, USD 6 billion rising to USD 12 billion in 2034.
- Asia Pacific takes a rising share of global revenue over the forecast period, from 38% in 2025 to 42% in 2034, with revenue growing from USD 6 billion to USD 12 billion.
- Middle East and Africa remains the smallest region throughout, at 4% of 2025 revenue and 4.8% by 2034.
- By type, the largest line in 2025 was Tableting Machine, at 28% of revenue and USD 4.42 billion.
- Others is projected to grow at 10.81% over the forecast period, the fastest of any type line.
- The United States is the largest single country market at USD 3.54 billion in 2025, 22.4% of global revenue.
Every year from 2020 to 2034 is reported, with revenue and growth for each line across five axes: by type, and by application, end user, technology and production capacity. The headline total carries bear, base and bull cases at USD 25.72 billion and USD 32.01 billion by 2034. The study also breaks out all five regions to country level, sets out the competitive landscape, and documents the method behind every estimate. Available as a PDF, with a free sample on request.